Published in Women's Health Weekly, March 30th, 2006
Nycomed and its U.S. collaborator NPS Pharmaceuticals Inc (NPSP) have successfully reached a milestone in the European registration process of Preotact. CHMP, the scientific committee of the European Medicines Agency (EMEA), has adopted a positive opinion, recommending marketing authorization for Preotact in Europe.
The indication recommended by CHMP is "treatment...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.